In summary, this study reveals that NEK2 is an underlying immune-related prognostic biomarker and may help in predicting outcomes, distinguishing immune and molecular characteristics and guiding proper therapies in ccRCC patients. This evidence concerns the gene NEK2 and nonpapillary renal cell carcinoma.